Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.35 | N/A | +77.66% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.35 | N/A | +77.66% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of optimism about the company's direction. However, they did not offer specific guidance for the upcoming quarters.
Management highlighted strong performance in their core business areas.
They expressed confidence in future growth despite not providing specific guidance.
Ligand Pharmaceuticals reported a strong earnings surprise, with EPS significantly exceeding expectations. The stock reacted positively, rising 13.83%, likely driven by investor confidence in the company's performance and future prospects. The lack of revenue data and guidance may leave some investors cautious, but the EPS beat suggests underlying strength in the business.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MACOM TECHNOLOGY SOL
Feb 10, 2014